Role of the Forkhead Box Family Protein FOXF2 in the Progression of Solid Tumor: Systematic Review

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 Dec 26

PMID 39724282

Authors

Yuzhen Zheng

Liusheng Wu

Zhenyu Hu

Hongying Liao

Xiaoqiang Li

Affiliations

Soon will be listed here.

Abstract

Background: FOXF2 was reported to involve in a variety of biological behaviors that include the development of the central nervous system, tissue homeostasis, epithelia-mesenchymal interactions, regulation of embryonic development, and organogenesis.

Purpose: Understanding how FOXF2 influences the growth and development of cancer could provide valuable insights for researchers to develop novel therapeutic strategies.

Results: In this review, we investigate the underlying impact of FOXF2 on tumor cells, including the transformation of cellular phenotype, capacity for migration, invasion, and proliferation, colonization of circulating cells, and formation of metastatic nodules. In addition, we discuss the molecular mechanisms of FOXF2 in different cancers, including hepatocellular, esophageal, breast, colon, lung, prostate gland, as well as its role in embryonic development.

Conclusion: FOXF2 is a gene encoding a forkhead transcription factor belonging to the Forkhead Box family. The protein functions by recruiting activation transcription factors and basic components to activate the transcription of genes that interact with the complex. This review provides an in-depth analysis of the FOXF2's function and pleiotropic roles in cancer development and progression.

References

Xu J, Liu H, Lan Y, Jiang R . The transcription factors Foxf1 and Foxf2 integrate the SHH, HGF and TGFβ signaling pathways to drive tongue organogenesis. Development. 2022; 149(21). PMC: 10655918. DOI: 10.1242/dev.200667. View

Barr F . Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001; 20(40):5736-46. DOI: 10.1038/sj.onc.1204599. View

Baumler A, Hantke K . Ferrioxamine uptake in Yersinia enterocolitica: characterization of the receptor protein FoxA. Mol Microbiol. 1992; 6(10):1309-21. DOI: 10.1111/j.1365-2958.1992.tb00852.x. View

Ben-Zvi A, Liebner S . Developmental regulation of barrier- and non-barrier blood vessels in the CNS. J Intern Med. 2021; 292(1):31-46. DOI: 10.1111/joim.13263. View

Aitola M, Carlsson P, Mahlapuu M, Enerback S, Pelto-Huikko M . Forkhead transcription factor FoxF2 is expressed in mesodermal tissues involved in epithelio-mesenchymal interactions. Dev Dyn. 2000; 218(1):136-49. DOI: 10.1002/(SICI)1097-0177(200005)218:1<136::AID-DVDY12>3.0.CO;2-U. View

Cai J, Tian A, Wang Q, Kong P, Du X, Li X . FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett. 2015; 367(2):129-37. DOI: 10.1016/j.canlet.2015.07.001. View

Blixt A, Mahlapuu M, Bjursell C, Darnfors C, Johannesson T, Enerback S . The two-exon gene of the human forkhead transcription factor FREAC-2 (FKHL6) is located at 6p25.3. Genomics. 1998; 53(3):387-90. DOI: 10.1006/geno.1998.5451. View

Cao G, Lin M, Gu W, Su Z, Duan Y, Song W . The rules and regulatory mechanisms of FOXO3 on inflammation, metabolism, cell death and aging in hosts. Life Sci. 2023; 328:121877. DOI: 10.1016/j.lfs.2023.121877. View

Chen J, Ding J, Wang Z, Zhu J, Wang X, Du J . Identification of downstream metastasis-associated target genes regulated by LSD1 in colon cancer cells. Oncotarget. 2017; 8(12):19609-19630. PMC: 5386709. DOI: 10.18632/oncotarget.14778. View

Chen X, Hu H, Liu J, Yang Y, Liu G, Ying X . FOXF2 promoter methylation is associated with prognosis in esophageal squamous cell carcinoma. Tumour Biol. 2017; 39(2):1010428317692230. DOI: 10.1177/1010428317692230. View

Nelson M, Carrano C, Szaniszlo P . Identification of the ferrioxamine B receptor, FoxB, in Escherichia coli K12. Biometals. 1992; 5(1):37-46. DOI: 10.1007/BF01079696. View

Chen Y, Xu H, Xu H, Liu C, Zhan M, Wang Z . Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia. Int J Biol Sci. 2023; 19(13):4242-4258. PMC: 10496513. DOI: 10.7150/ijbs.85739. View

Dou C, Jin X, Sun L, Zhang B, Han M, Li T . FOXF2 deficiency promotes hepatocellular carcinoma metastasis by inducing mesenchymal-epithelial transition. Cancer Biomark. 2017; 19(4):447-454. DOI: 10.3233/CBM-170139. View

10.

Fang H, Fu K, Shi P, Zhao Z, Yang F, Liu Y . Forkhead box F2/ Lysyl oxidase like 1 contribute to epithelial-mesenchymal transition and angiogenesis in thyroid cancer. Cell Signal. 2023; 113:110956. DOI: 10.1016/j.cellsig.2023.110956. View

11.

Geng Y, Deng L, Su D, Xiao J, Ge D, Bao Y . Identification of crucial microRNAs and genes in hypoxia-induced human lung adenocarcinoma cells. Onco Targets Ther. 2016; 9:4605-16. PMC: 4966693. DOI: 10.2147/OTT.S103430. View

12.

He W, Kang Y, Zhu W, Zhou B, Jiang X, Ren C . FOXF2 acts as a crucial molecule in tumours and embryonic development. Cell Death Dis. 2020; 11(6):424. PMC: 7275069. DOI: 10.1038/s41419-020-2604-z. View

13.

Higashimori A, Dong Y, Zhang Y, Kang W, Nakatsu G, Ng S . Forkhead Box F2 Suppresses Gastric Cancer through a Novel FOXF2-IRF2BPL-β-Catenin Signaling Axis. Cancer Res. 2018; 78(7):1643-1656. DOI: 10.1158/0008-5472.CAN-17-2403. View

14.

Hirata H, Ueno K, Shahryari V, Deng G, Tanaka Y, Tabatabai Z . MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One. 2013; 8(1):e55502. PMC: 3559583. DOI: 10.1371/journal.pone.0055502. View

15.

Jackson B, Carpenter C, Nebert D, Vasiliou V . Update of human and mouse forkhead box (FOX) gene families. Hum Genomics. 2010; 4(5):345-52. PMC: 3500164. DOI: 10.1186/1479-7364-4-5-345. View

16.

Jain M, Shareef A, Likus W, Cieslar-Pobuda A, Ghavami S, Los M . Inhibition of miR301 enhances Akt-mediated cell proliferation by accumulation of PTEN in nucleus and its effects on cell-cycle regulatory proteins. Oncotarget. 2016; 7(15):20953-65. PMC: 4991504. DOI: 10.18632/oncotarget.7996. View